BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 14689107)

  • 21. A 26-week, prospective, open-label, uncontrolled, multicenter study to evaluate the effect of an escalating-dose regimen of trandolapril on change in blood pressure in treatment-naive and concurrently treated adult hypertensive subjects (TRAIL).
    Tytus RH; Burgess ED; Assouline L; Vanjaka A
    Clin Ther; 2007 Feb; 29(2):305-15. PubMed ID: 17472822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of combination therapy in the treatment of hypertension: focus on valsartan plus amlodipine.
    Ferri C; Croce G; Desideri G
    Adv Ther; 2008 Apr; 25(4):300-20. PubMed ID: 18449492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome.
    Leenen FH
    Can J Cardiol; 2004 Aug; 20 Suppl B():77B-82B. PubMed ID: 15309209
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prescribing patterns in hypertension: the emerging role of fixed-dose combinations for attaining BP goals in hypertensive patients.
    Neutel JM
    Curr Med Res Opin; 2008 Aug; 24(8):2389-401. PubMed ID: 18616863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The 2004 Canadian recommendations for the management of hypertension: Part II--Therapy.
    Khan NA; McAlister FA; Campbell NR; Feldman RD; Rabkin S; Mahon J; Lewanczuk R; Zarnke KB; Hemmelgarn B; Lebel M; Levine M; Herbert C;
    Can J Cardiol; 2004 Jan; 20(1):41-54. PubMed ID: 14968142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypertension: the rediscovery of combination therapy.
    Prisant LM; Doll NC
    Geriatrics; 1997 Nov; 52(11):28-30, 33-8. PubMed ID: 9371101
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Healthcare benefits of very-low-dose combination treatment used in the management of hypertension.
    Ambrosioni E
    J Hypertens Suppl; 2001 Nov; 19(4):S29-36. PubMed ID: 11848260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Modern antihypertensive drug therapy].
    Spieker C; Barenbrock M; Rahn KH
    Fortschr Med; 1996 Nov; 114(32):425-30. PubMed ID: 9064265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension.
    Calhoun DA; Glazer RD; Pettyjohn FS; Coenen PD; Zhao Y; Grosso A
    Curr Med Res Opin; 2008 Aug; 24(8):2303-11. PubMed ID: 18593517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A factorial study of combination hypertension treatment with metoprolol succinate extended release and felodipine extended release results of the Metoprolol Succinate-Felodipine Antihypertension Combination Trial (M-FACT).
    Frishman WH; Hainer JW; Sugg J;
    Am J Hypertens; 2006 Apr; 19(4):388-95. PubMed ID: 16580575
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose monotherapy vs low-dose combination therapy of calcium channel blockers and angiotensin receptor blockers in mild to moderate hypertension.
    Andreadis EA; Tsourous GI; Marakomichelakis GE; Katsanou PM; Fotia ME; Vassilopoulos CV; Diamantopoulos EJ
    J Hum Hypertens; 2005 Jun; 19(6):491-6. PubMed ID: 15759025
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Basic principles and possible variations in combination antihypertensive therapy].
    Scholze J
    Z Arztl Fortbild Qualitatssich; 1997 Mar; 91(2):155-63. PubMed ID: 9244658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment strategies in essential arterial hypertension].
    Waeber B
    Rev Prat; 1999 Mar; 49(5):520-5. PubMed ID: 10358402
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension.
    Waeber B
    Expert Rev Cardiovasc Ther; 2003 May; 1(1):43-50. PubMed ID: 15030296
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ESH-ESC guidelines for the management of hypertension.
    Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
    Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimizing management of hypertension with combination therapy: considerations for the nurse practitioner.
    Roberts ME; Epstein BJ
    J Cardiovasc Nurs; 2009; 24(5):380-9. PubMed ID: 19707098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Initial combination therapy for rapid and effective control of moderate and severe hypertension.
    Franklin SS; Neutel JM
    J Hum Hypertens; 2009 Jan; 23(1):4-11. PubMed ID: 18615100
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The future of antihypertensive treatment.
    Israili ZH; Hernández-Hernández R; Valasco M
    Am J Ther; 2007; 14(2):121-34. PubMed ID: 17414579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.